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AbstrAct
Macrophages are a major cellular constituent of the tumour stroma and 
contribute to breast cancer prognosis. The precise role and treatment strategies to 
target macrophages remain elusive. As macrophage infiltration is associated with poor 
prognosis and high grade tumours we used the THP-1 cell line to model monocyte-
macrophage differentiation in co-culture with four breast cancer cell lines (MCF7, 
T47D, MDA-MB-231, MDA-MB-468) to model in vivo cellular interactions. Polarisation 
into M1 and M2 subtypes was confirmed by specific cell marker expression of ROS and 
HLA-DR, respectively. Co-culture with all types of macrophage increased migration of 
ER-positive breast cancer cell lines, while M2-macrophages increased mammosphere 
formation, compared to M1-macrophages, in all breast cancer cells lines. Treatment of 
cells with Zoledronate in co-culture reduced the “pro-tumourigenic” effects (increased 
mammospheres/migration) exerted by macrophages. Direct treatment of breast 
cancer cells in homotypic culture was unable to reduce migration or mammosphere 
formation. 
Macrophages promote “pro-tumourigenic” cellular characteristics of breast 
cancer cell migration and stem cell activity. Zoledronate targets macrophages within 
the microenvironment which in turn, reduces the “pro-tumourigenic” characteristics 
of breast cancer cells. Zoledronate offers an exciting new treatment strategy for both 
primary and metastatic breast cancer.
IntroductIon
Breast cancer is the most common disease in women 
in the Western world with an incidence rate of 600,000 
and a mortality rate of 200,000 each year [1]. Breast 
cancer diagnosis and treatment has significantly improved 
in recent years with increased disease-free survival in 
breast cancer patients. Despite these improvements, a 
significant proportion of breast cancers are either resistant 
to treatment or show disease recurrence [2, 3]. It is 
essential that we improve our understanding of cancer 
biology and the complex interplay between the different 
cell types driving cancer, in order to develop more targeted 
therapies.
Loss of control of proliferation and resistance to 
apoptosis/necrosis is considered a hallmark of many 
cancer types including breast cancer [4]. Subsequent 
to primary tumour formation, metastasis may occur 
whereby cells acquire migratory capacity, invade into the 
surrounding tissue, enter the blood stream and lymphatic 
system and then extravasate and colonise a secondary site 
[5]. Recurrences at metastatic sites represent a major cause 
of mortality in breast cancer patients [6, 7]. Resistance 
to therapy impedes the improvement of breast cancer 
mortality rates within the clinic. Research suggests that 
cancer stem cells (CSCs) play an important role in breast 
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cancer and therapy resistance [8] emphasising the need 
for new treatment strategies [9, 10]. Additionally, CSCs 
may be responsible for the initiation and regeneration of 
tumours [11, 12] and given their quiescent nature may be 
responsible for lasting residual disease and underlying 
tumour dormancy [8]. CSCs can be identified by various 
cellular markers including CD44+/CD24- and ALDH1 
expression, or by their ability to form mammospheres 
[13-15]. 
Breast cancer is a solid tumour therefore its 
surrounding microenvironment is particularly important. 
In breast cancer stroma, macrophages can occupy more 
than fifty percent of the breast tumour mass with studies 
showing a correlation between macrophage density 
and poor patient prognosis [16-19]. Macrophages are 
heterogeneous in population and can be classified as 
M1 or M2, polarising to each dependent on the stimuli 
present at time of activation [20, 21]. In tumours it has 
been suggested that M2 macrophages are most prevalent 
and that they directly promote breast cancer growth by 
secreting breast tumour mitogens and angiogenic factors 
[22-24] and are associated with poor prognosis in breast 
cancer patients [16, 25]. 
There is clear evidence that macrophages are a key 
component of the tumour stroma and influence breast 
cancer prognosis, it is therefore essential we understand 
the exact mechanisms and develop new treatments to 
target the microenvironment. One promising treatment is 
Zoledronate (zoledronic acid) a bisphosphonate used in 
the treatment of osteoporosis and advanced breast cancer 
due to its positive actions within bone. However it was 
observed that Zoledronate may also inhibit breast cancer 
progression and invasion [26] with recent data suggesting 
that which recent data suggests these actions may be via 
M2 pro-tumourigenic macrophages rather than directly on 
breast cancer cells [27].
Our study uses co-culture approaches to provide 
further insight into the mechanisms of tumour-associated 
macrophages by examining the influence of macrophages 
upon breast cancer cell proliferation, apoptosis, migration 
and stem-cell activity. Crucially, we demonstrate 
that Zoledronate treatment can overcome the “pro-
tumourigenic” effects that macrophages exert within the 
microenvironment by reducing breast cancer migration 
and mammosphere formation. 
results
Macrophage infiltration in primary breast 
tumours
To confirm that macrophage infiltration is associated 
with poor prognosis in primary breast cancer, we analysed 
the expression of CD68 protein within a tissue microarray 
Figure 1: Macrophage infiltration in primary breast tumours. IHC staining of formalin fixed breast cancer samples for CD68 A. 
Image showing CD68 expression marking the macrophage cell type B. Kaplan Meier analysis of CD68 expression grouped into high and 
low expression. High macrophage infiltration predicts decreased recurrence free survival C. Representative TMA core of breast tumours 
showing low macrophage infiltration D. Representative TMA core of breast tumours showing high macrophage infiltration
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(TMA) containing formalin fixed tumours from 129 breast 
cancer patients (Figure 1A). High expression of CD68 and 
therefore high macrophage infiltration was predictive of 
poor recurrence free survival (p = 0.02) (Figure 1B). For 
analysis, expression of CD68 was divided into two groups, 
‘low’ (Figure 1C) and ‘high’ (Figure 1D) relative to mean 
expression. Additionally, high macrophage infiltration was 
associated with more aggressive tumours, represented 
by high grade tumours (p = 0.02) and lymph node 
involvement (p = 0.04) (Table 1), but was not associated 
with ER or HER2 status. We also assessed CD68 mRNA 
expression in a cohort of 1107 breast cancer tumour 
tissue samples (containing tumour stroma) comprising 
six publically available gene expression data sets [28]. 
Increased expression was observed in both Luminal B 
and ERBB2 expressing tumours compared to normal-like 
breast tissue (Figure 2A). As with the protein data, grade 
3 tumours showed significantly higher expression of the 
macrophage marker CD68 (Figure 2B).
Generating differentiated macrophages
The THP-1 monocytic cell line was used as 
a model to generate differentiated macrophages for 
co-culture experiments. Phorbol myristate acetate 
(PMA) treatment induced differentiation measured 
by an increase in adherence (Figure 3A) and changes 
in morphology, indicated by altered forward scatter 
(FSC) and side scatter (SCC) FACS plots (Figure 3B). 
Flow cytometry analysis showed that macrophages 
expressed significantly increased levels of CD14 (Figure 
3C) and CD11b (Figure 3D) confirming macrophage 
differentiation. In addition, lysotracker was used to 
confirm THP-1 monocyte to macrophage differentiation, 
with differentiated macrophages showing increased 
lysosome accumulation (Supplementary Figure 1). Further 
treatment of macrophages with LPS/IFN or IL4/IL13 
induced polarisation into M1 and M2 subtypes marked 
by increased ROS production (Figure 3E) and HLA-DR 
(Figure 3F) expression, respectively. 
table 1: Clinico-pathological characteristics of breast cancer patients in relation to macrophage count (CD68 
expression). Distributions of tumour macrophage number (CD68 expression) categorisations according to clinical-pathological 
and molecular parameters (percentages in parenthesis). Macrophage count was divided into low and high by the median value. 
High level of macrophage infiltration was associated with higher tumour grade and lymph node metastasis. 1Kruskel Wallis 
2Spearman’s Rho 3Fisher’s Exact. 
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Monocytes and macrophages have no major 
effects on breast cancer cell growth, apoptosis or 
necrosis
We co-cultured two ER+ and two ER- breast 
cancer cell lines, (MCF7, T47D, MDA-MB-231, MDA-
MB-468), with THP-1 monocytes, macrophages and M1/
M2 subtypes for 48hrs (Supplementary Figure 2). The 
only significant change in proliferation observed was 
with the co-culture of THP-1 monocytes and T47D cells 
where an increase in proliferation was observed (Figure 
4A). Cell apoptosis determined by Annexin V staining 
was only significantly changed with the co-culture of 
THP-1 monocytes with MDA-MB-468 cells, where a 
reduction in apoptosis was seen (Figure 4B). Analysis of 
necrosis marked by Propidium Iodide staining showed a 
reduction in necrosis with co-culture of macrophages and 
M2 macrophages with T47D cells (Figure 4C). Overall, no 
consistent changes or patterns following co-culture were 
observed across the breast cancer cell lines. 
Monocytes and macrophages affect migration 
dependent upon breast cancer subtype
Within ER+ breast cancer cell lines, co-culture 
with all types of macrophages including M1 and M2 
subtypes increased breast cancer migration compared to 
breast cancer cell lines alone, or in co-culture with THP-1 
monocytes. A small increase in migration was observed 
with co-culture of THP-1 monocytes and MCF7 cells 
(Figure 5A/5B). In comparison, co-culture of ER- breast 
cancer cells with THP-1 monoctyes or macrophages 
caused a decrease in migration compared to breast cancer 
cells alone. Interestingly, M1 and M2 subtypes caused 
increased migration in ER- breast cancer cells compared 
to co-culture with general macrophages (Figure 5C/5D). 
Figure 2: CD68 is more highly expressed in high grade breast tumours of ERRB2 and Luminal B subtypes. mRNA 
analysis of breast cancer samples. CD68 gene expression (“203507_at” probeset, batch corrected data from six published studies) was used 
as a marker of macrophages and expression analysed within the breast cancer samples. A. Expression levels were compared in breast cancer 
subtypes (ERBB2, Basal, Luminal A, Luminal B) to that in normal-like samples. Macrophage infiltration is increased in Luminal A and 
ERBB2 subtypes compared to normal-like. B. Analysis of CD68 expression to grade showed significant positive correlation. 
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M2 macrophages increase mammosphere 
formation in breast cancer cell lines
Within ER+ breast cancer cell lines, co-culture with 
M2 macrophages significantly increased mammosphere 
formation compared to co-culture with breast cancer cell 
lines alone or with M1 macrophages. Interestingly, within 
the T47D cell line an increase in mammosphere formation 
was observed with the co-culture of THP-1 monocytes 
(Figure 6A/6B). Co-culture of both ER- breast cancer cell 
lines with M2 macrophages also increased mammosphere 
formation in comparison to breast cancer cell lines co-
cultured with M1 macrophages. However, unlike the ER+ 
cell lines, co-culture with all other cells types (THP1- 
monocytes, macrophages and M1 macrophages) resulted 
Figure 3: Differentiation of THP-1 monocytes into macrophages. THP-1 monocytes were treated for three days with PMA to 
induce macrophage differentiation A. Bright-field imaging shows increased adherence B. FACS analysis of SSC and FSC confirmed altered 
morphology following addition of PMA (right panel). Cells were further treated with IFN /LPS (M1) or IL4/IL13 to achieve macrophage 
polarisation. FACS analysis showed increased C. CD14 expression and d. CD11b in macrophages vs THP-1 monocytes E. FACS analysis 
of ROS activity showed increased expression in THP-1 cells? treated with IFN/LPS F. FACS analysis of HLA-DR expression was increased 
in cells treated with IL4/IL13. Bar charts represent the mean % of cells, ±SEM. P values were generated using a two sided t-test assuming 
equal variance compared to either THP-1 monocytes, or between IFN/LPS and IL4/IL13 treated cells * indicates significance, p < 0.05. 
**p < 0.01 ***p < 0.001
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in a reduction in mammosphere formation (Figure 6C/6D). 
Zoledronate targets the macrophage 
microenvironment to reduce breast cancer cell 
migration and mammosphere formation
Having shown the effects of monocytes and 
macrophages on breast cancer cell migration and 
mammosphere formation, we used the in vitro co-culture 
system as a model to test the effects of the bisphosphonate 
Zoledronate, both on breast cancer cells alone and within 
the co-culture setting. Zoledronate treatment of MCF7 
and MDA-MB-231 cells in homotypic culture caused 
no reduction in migration or mammosphere formation. 
In fact, a small increase was observed in mammosphere 
formation in MDA-MB-231 cells. However, Zoledronate 
treatment of breast cancer cells whilst in co-culture with 
macrophages significantly reduced breast cancer migration 
and mammosphere formation (Figure 7). 
Figure 4: Effects of monocytes and macrophages on breast cancer growth, apoptosis and necrosis. Breast cancer cell lines 
(MCF7, T47D, MDA-MB-231 and MDA-MB-468) were co-cultured with THP1-monocytes, macrophages or M1/M2 macrophages and 
compared to breast cancer cells alone. A. Proliferation was assessed by Alamar blue staining, B. apoptosis by Annexin staining and FACS 
analysis C. and necrosis by Propidium Ioidine staining and FACS analysis. Bar charts represent the mean % of cells, ±SEM. P values were 
generated using a two sided t-test assuming equal variance compared to breast cancer cells alone. * indicates significance, p < 0.05. ** p 
< 0.01 ***p < 0.001
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Figure 5: Effects of monocytes and macrophages on cell migration. Breast cancer cell lines a) MCF7, b) T47D, c) MDA-
MB-231 and d) MDA-MB-468 were co-cultured with THP1-monocytes, macrophages or M1/M2 macrophages and compared to breast 
cancer cells alone. Migration of breast cancer cells was assessed by transwell inserts. Bar charts represent the mean % of cells, ±SEM. P 
values were generated using a two sided t-test assuming equal variance compared to breast cancer cells alone , or between cells co-cultured 
with M1 and M2 macrophages * indicates significance, p < 0.05. ** p < 0.01 ***p < 0.001.
Figure 6: Effects of monocytes and macrophages on mammosphere formation. Breast cancer cell lines a) MCF7, b) T47D, 
c) MDA-MB-231 and d) MDA-MB-468 were co-cultured with THP1-monocytes, macrophages or M1/M2 macrophages and compared to 
breast cancer cells alone. Mammosphere formation of breast cancer cells was assessed. Bar charts represent the mean % of cells, ±SEM. P 
values were generated using a two sided t-test assuming equal variance compared to breast cancer cells alone , or between cells co-cultured 
with M1 and M2 macrophages * indicates significance, p < 0.05. ** p < 0.01 ***p < 0.001.
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Figure 7: Targeting macrophages with Zoledronate reduces breast cancer cell migration and mammosphere formation. 
Breast cancer cell lines (MCF7, T47D, MDA-MB-231 and MDA-MB-468) were treated with 1uM Zoledronate for 48hrs (white bars). 
Additionally, cells were treated with Zoledronate in co-culture with THP1-monocytes, macrophages or M1/M2 macrophages and compared 
to breast cancer cells alone. Mammosphere formation and migration of breast cancer cells was assessed following treatment and co-culture. 
Bar charts represent the mean % of cells; ±SEM. P values were generated using a two sided t-test assuming equal variance. Comparisons 
made were between untreated breast cancer cells and Zoledronate treated breast cancer cells, and comparison between breast cancer treated 
cells (alone) and treated cells in co-cultured with THP-1, macrophages and M1 and M2 macrophages * indicates significance, p < 0.05. 
**p < 0.01 ***p < 0.001
Figure 8: Zoledronate targets the pro-tumourigenic macrophage microenvironment. Monocytes can be polarized into two 
distinct types of macrophages, M1 and M2, using phorbol 12-myristate 13-acetate (PMA), interferon gamma (IFN-γ) and lipopolysaccharide 
(LPS) or PMA and interleukin 4 (IL-4) and interleukin 13 (IL-13) respectively. M1 macrophages, classically referred to as “pro-inflammatory 
macrophages” are known to secrete many factors such as tumour necrosis factor alpha (TNF-α) and reactive oxygen species (ROS) and 
likely unknown factors. Within our model M1 macrophages stimulate breast cancer migration. M2 macrophages classically referred to 
as “pro-tumourigenic macrophages” are known to secrete numerous factors including matrix metalloproteinase’s (MMPs) and epidermal 
growth factor (EGF). Within our model M2 macrophages stimulate breast cancer migration and stem cell-like activity. The interaction 
between macrophages and cancer cells is bi-directional whereby cancer cells also secrete proteins, for example colony stimulating factor 
(CSF) which recruits M2 macrophages to the tumour. Zoledronate inhibits the effects that both M1 and M2 macrophages exert upon breast 
cancer cells, with no direct effect on the breast cancer cells in the absence of a macrophage microenvironment. The mechanism of action of 
Zoledronate is therefore likely to effect the interaction between macrophages and breast cancer cells.
Oncotarget14695www.impactjournals.com/oncotarget
dIscussIon
Macrophages are a major component of the breast 
cancer microenvironment. In this study, we have identified 
increased macrophage infiltration within Luminal B and 
ERBB2 subtypes, and demonstrated that macrophage 
infiltration is associated with tumour recurrence, high 
grade and positive lymph node status which is consistent 
with previous published literature [16-19]. Using in 
vitro models we have also successfully identified a 
role for macrophages and monocytes in breast cancer, 
dependent upon breast cancer subtype, and have shown 
how macrophages exert pro-tumourigenic effects through 
increasing migration and mammosphere formation, a 
marker of stem-like cell activity. 
We used the THP-1 monocyte cell line as a 
model for macrophage differentiation and polarisation 
and to model the in vivo microenvironment of solid 
breast tumours. THP-1 cells have been widely used in 
macrophage research and have been shown to closely 
model primary macrophages extracted from whole blood 
[29-31]. Subsequently we polarized macrophages into 
distinct subtypes using LPS/IFN or IL4/IL13 to establish 
M1 and M2 subtypes respectively [32, 33]. A number of 
molecular markers have been identified to distinguish 
between macrophage subtypes, within this study we used 
ROS and HLA-DR which showed significant differences 
and confirmed adequate polarization between M1 and M2 
subtypes respectively. 
Having established the differentiation and 
polarization of macrophages, co-culture experiments were 
performed using a panel representing ER+ and ER- breast 
cancer cell lines to assess key cancer cell characteristics. 
ER+ breast cancer migration was increased with co-
culture of macrophages, whilst in ER- breast cancer 
migration was inhibited. Despite this, the presence of 
macrophages significantly increased migration compared 
to monocytes. M2 macrophages significantly increased 
mammosphere formation across all breast cancer cell 
lines. This suggest that the specialised M2 macrophages, 
unlike M1 macrophages, secrete a specific set of proteins 
that directly regulate stem cell activity, and support the 
idea that tissue associated macrophages, which contribute 
to poor prognosis, are of an M2 phenotype. Identification 
of these specific “stem-like cell promoting” proteins will 
aid in developing novel drugs to treat the pro-tumourigenic 
microenvironment. Using our model we have identified 
a potential treatment to overcome the pro-tumourigenic 
effects of the macrophage microenvironment. Treatment 
of cancer cells with Zoledronate, only when in co-culture, 
reduced migration consistent with a recent publication 
[27]. In addition we identified novel effects, whereby 
Zoledronate reduced breast cancer mammosphere 
formation when in co-culture represented schematically 
in Figure 8. Zoledronate is a nitrogen-containing 
bisphosphonate, Zoledronate (zoledronic acid) initially 
used in the treatment of osteoporosis and more recently in 
advanced breast cancer due to its positive actions within 
bone. However it was observed that Zoledronate may 
also inhibit breast cancer progression and invasion [26]. 
In vitro and in vivo studies have shown anti-tumourigenic 
effects on breast cancer tumours, including the prevention 
of metastasis into the extracellular matrix however its 
exact mechanism of action is unclear [34, 35]. Growing 
evidence suggests that Zoledronate may not act directly on 
cancer cells, but within the microenvironment, potentially 
by reprogramming macrophages into a non-tumourigenic 
phenotype. In vivo murine models treated with Zoledronate 
showed impaired M2 macrophage recruitment and a 
switch from M2 to M1 macrophage phenotype [34, 36, 
37]. This may be as a result of reduced IL13 expression, 
a key cytokine for the activation of M2 macrophages [38, 
39]. The latter suggests that Zoledronate may have specific 
effects via M2 pro-tumourigenic macrophages rather than 
directly on breast cancer cells [27]. This is consistent 
with our results and would suggest that Zoledronate acts 
upon M2 macrophages to re-polarize cells into an M1 
phenotype. In turn, this would prevent migration and 
mammosphere activity, both essential characteristics 
leading to tumour progression and metastasis, and could 
explain the decreased survival of patients correlating to 
macrophage infiltration. The mechanism of macrophage 
reprogramming exerted by Zoledronate is yet to be 
discovered. Despite this, Zoledronate is an exciting new 
treatment for breast cancer patients that can be used in both 
a primary and metastatic setting, to overcome the powerful 
pro-tumourigenic effects of the microenvironment. 
In conclusion, macrophages are a key component 
of the breast cancer microenvironment which when 
present, in particular the M2 subtype, predict poor 
prognosis, through the promotion of migration and stem 
cell activity. Macrophages therefore represent a new 
therapeutic target for the treatment of breast cancer. 
Zoledronate exerts anti-tumourigenic effects by targeting 
the macrophage microenvironment to reduce cancer cell 
migration and stem cell activity. Additional clinical trials, 
in a neoadjuvant and metastatic setting are required, with 
increased dosing regimes, to fully assess the potential 
clinical benefit of Zoledronate in breast cancer treatment. 
MATERiALs AnD METHoDs
Cell lines
All cell lines were purchased from ATCC; MDA-
MB-231, MDA-MB-468 (ER negative) MCF7, and 
T47D (ER positive) and THP-1 (monocytes). Cell 
lines were authenticated by multiplex PCR assay using 
the AmpFlSTR Indentifiler PCR amplification kit 
(Applied Biosystems, Life Technologies Corporation, 
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#4322288) and confirmed as mycoplasma free. THP-
1, MDA-MB-231 and MDA-MB-468 were cultured in 
RPMI complete medium (RPMI/10% FCS/1% Sodium 
pyruvate/2mM L-glutamine/PenStrep) whilst MCF7 
and T47D were grown in DMEM complete medium 
(DMEM/10% FCS/2mM L-glutamine/PenStrep). Cells 
were maintained in a humidified incubator at 37oC at an 
atmospheric pressure of 5% (v/v) carbon dioxide/air. 
Monocyte-Macrophage differentiation
THP-1 monocytes were plated (200,000 cells/ml) 
in RPMI supplemented with 200nM Phorbol myristate 
acetate (PMA) for 72 hrs to achieve macrophage 
differentiation. Media was then supplemented with either 
100ng/ml IFN-ƴ and 100 ng/ml LPS (M1 macrophage 
subtype) or 20 ng/ml IL4 and 20 ng/ml IL13 (M2 
macrophage subtype) and cultured for a further 5 
days prior to harvesting, to achieve polarization into 
macrophage subgroups. 
imaging
Imaging of THP-1 monocytes/macrophages was 
carried out using an Olympus CKX41SF2-5 microscope, 
10X at magnification. For fluorescence imaging, an X-cite 
120 fluorescence camera and illumination system was 
used. Images were taken after the 8 day incubation to 
induce macrophage differentiation. 
Monocyte-macrophage flow cytometry analysis
Following monocyte-macrophage differentiation and 
polarization 400,000 cells were incubated with 4ul CD14-
PE, CD11b-PE, HLA-DR-PE or 5 µM CM-H2DCFDA in 
the dark for 10 minutes at 37ºC. Cells were resuspended 
in 500ul PBS and fluorescence analyzed by FACS. Cells 
were analysed using the Becton Dickinson FACS Calibur 
and data was processed using BD CellQuest™ Pro V6.0 
and analysed using WinMDI V2.8 software.
Lysotracker
Untreated THP-1 monocytes or THP-1 cells treated 
with PMA, were incubated at a density of 1 x106 cells/ml 
with lysotracker reagent at 37ºC for 1 hour, followed by 
fixation with 4% formalin for 15 minutes and mounted 
with Prolong DAPI. 
In vitro co-culture model
Breast cancer cells (6 x105) were co-cultured with 
either THP-1 monocytes, macrophages, M1 macrophages 
or M2 macrophages (6 x105), or breast cancer cells alone 
in 6-well 24 mm Transwell® sterile plates, separated by 
a 0.4 µm pore polycarbonate membrane insert (Corning, 
catalogue #3412). Cells were incubated for 48 hours at 
37°C before harvesting for subsequent analysis of breast 
cancer cell lines. 
Mammosphere culture
Following co-culture, breast cancer cells were 
collected and a single cell suspension prepared using 
enzymatic (1x Trypsin-EDTA, Sigma Aldrich, #T3924), 
and manual disaggregation (25 gauge needle). Cells 
were plated at a density of 500 cells/cm2 in non-adherent 
conditions in mammosphere medium (DMEM-F12/
B27/20ng/ml EGF/PenStrep). Cells were grown for 5 
days and maintained in a humidified incubator at 37°C at 
an atmospheric pressure in 5% (v/v) carbon dioxide/air. 
Mammospheres > 50µm were counted using an eye piece 
graticule. 
Migration assay
Following co-culture, breast cancer cells were 
collected and migration assessed using transwell chambers 
with a diameter of 6.5 mm and a pore size of 8 µm 
(Corning, Inc. #3422). Cells (50,000) were resuspended 
in 150 µl serum-free media and added to the upper 
migration chamber. Cells were allowed to migrate for 
5 hours (MDA-MB-231) or overnight (MCF7, T47D, 
MDA-MB-468) towards media containing 10% FCS. 
Non-migrated cells were removed using a cotton swab. 
Migrated cells situated on the lower side of membranes 
were stained for 10 minutes with crystal violet solution 
(1% v/v crystal violet, 70% ethanol). Cells were viewed 
and counted using an Olympus CKX41SF2-5 microscope 
at X20 magnification (cells in 15 fields were counted). 
Experiments were repeated in triplicate. The percentage 
of cells that had migrated was calculated. 
Cell growth assay
Following co-culture breast cancer cells were plated 
in a 96-well tissue-culture plates at a ratio 2500 cells/ 100 
µl (MDA-MB-231) or 5000 cells/ 100 µl (MDA-MB-468, 
MCF7, T47D). Cells were incubated for 24 hours at 37°C, 
the media was removed and 20 µl alamarBlue® (AB)/ 
complete media (1:20) was added to each well. The pate 
was re-incubated for 1 hour at 37°C. Fluorescence was 
measured at an excitation wavelength of 544 nm and an 
emission wavelength of 590 nm on a FLUOstar Omega 
software V1.20 (BMG Labtech). After measurement the 
AB/ complete media solution was removed and the plate 
washed twice with PBS. Complete media (100 µl/ well) 
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was added for a further 24 hours and the process repeated. 
Cell apoptosis/necrosis
Following co-culture, 400,000 breast cancer cells 
were re-suspended in 500 µl 1X Annexin V binding 
buffer with 5 µl of Annexin V-FITC (Apoptosis) and 5 µl 
Propidium Iodide (Necrosis). Cells were incubated in the 
dark for 15 minutes at room temperature. Cells were then 
analysed by FACS. Cells were analysed using the Becton 
Dickinson FACS Calibur and data was processed using 
BD CellQuest™ Pro V6.0 and analysed using WinMDI 
V2.8 software.
Zoledronate (ZoL) treatment
Breast cancer cells were co-cultured with or without 
THP-1 monocytes, macrophages, M1 and M2 subtypes 
as previously described and treated with or without 1µM 
ZOL (Zoledronic acid, Novartis) and incubated for 48 
hours at 37°C. Breast cancer cells were collected and 
migration and mammosphere formation assayed. 
Primary breast cancer microarray
Affymetrix gene expression data representing a 
total of 1107 primary breast tumours from six previously 
published microarray studies [40-45] were integrated 
as described previously using ComBat [46] to remove 
batch effects [28]. Centroid prediction [47] was used to 
assign the tumours from each dataset to the five Norway/
Stanford subtypes (Basal, Luminal A, Luminal B, ERBB2 
and Normal-like [48]. Histological grade information was 
taken from the original datasets.
Primary breast cancer tissue microarray
The breast cancer samples were obtained from 
144 patients undergoing surgical resection at Malmo 
University Hospital, Sweden, between 2001 and 2002 and 
all patients received adjuvant chemotherapy. Additional 
clinical information has been previously described [49]. 
The study was approved by the regional ethical committee 
in Lund, Sweden. 
FFPE TMA sections were deparaffinised, rehydrated 
and antigen retrieval was performed using Dako target 
retrieval solution (Dako). For IHC, anti-CD68 antibody 
was used (M0814. DAKO) at a dilution of 1 in 1500. 
Isotype control was performed to ensure antibody 
specificity. The number of CD68-positive cells within each 
TMA core was counted at x400 magnification and patients 
subsequently divided into subgroups by the mean into low 
and high expression.
statistical methods
Throughout the paper data is represented as mean 
±SEM taken over a minimum of three independent 
experiments. Statistical significance was measured using 
parametric testing, assuming equal variance, with standard 
t-Tests for two paired samples used to assess difference 
between test and control samples, unless otherwise stated. 
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